Pedro Santabarbara

About

Pedro Santabarbara, M.D., Ph.D., is chief medical officer. He is responsible for the overarching clinical strategies for Infinity’s pipeline as well as overseeing the company’s clinical drug safety programs. Prior to joining Infinity in 2010, Dr. Santabarbara spent five years with PharmaMar, where he most recently led the development and approval of Yondelis® (trabectedin). Prior to PharmaMar, he served as vice president of clinical research oncology at OSI Pharmaceuticals, Inc., where he led the successful approval of Tarceva® (erlotinib). Before joining OSI, Dr. Santabarbara led development activities for Campath® (alemtuzumab) at ILEX Oncology, Inc. Earlier in his career, Dr. Santabarbara was also employed at Rhone Poulenc Rorer where he led the North American clinical development of Taxotere® (docetaxel), which he drove to approval in breast cancer and designed the strategy for non-small cell lung cancer. He also contributed to the development of Taxol® (paclitaxel) while at Br

Investment Focus

Location

Cambridge, US